Brain dysfunction in fibromyalgia and somatization disorder using proton magnetic resonance spectroscopy: A controlled study

Acta Psychiatrica Scandinavica

Volumn 126, Issue 2, 2012, Pages 115-125

  Fayed, N ^a   Andres, E ^b   Rojas, G ^a   Moreno, S ^c   Serrano Blanco, A ^d   Roca, M ^e   Garcia Campayo, J ^c  

^a Division of Dermatology Quiron Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d Sant Joan de Deu   (Spain)

^e UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Cingulate cortex; Fibromyalgia; Glutamate; Magnetic resonance spectroscopy; Somatization disorder

Indexed keywords

CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL;

ADULT; ANXIETY; ARTICLE; BRAIN DYSFUNCTION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; FEMALE; FIBROMYALGIA; HIPPOCAMPUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAIN; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; QUESTIONNAIRE; SOMATIZATION; SPAIN;

ADULT; BRAIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FIBROMYALGIA; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEUROIMAGING; PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES; SOMATOFORM DISORDERS;

EID: 84863579840     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2011.01820.x     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR, 4th edn (text revision). Washington, DC, USA: American Psychiatric Association, 2000.
2. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Comittee. Arthritis Rheum 1990;33:160-172.
3. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-1343.
4. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003;105:403-413.
5. Wood PB, Patterson JC, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007;8:51-58.
6. Sundgren PC, Petrou M, Harris RE et al. Diffusion-weighted and diffusion tensor imaging in fibromyalgia patients: a prospective study of whole brain diffusivity, apparent diffusion coefficient, and fraction anisotropy in different regions of the brain and correlation with symptom severity. Acad Radiol 2007;14:839-846.
7. Garcia-Campayo J, Sanz C, Baringo T, Ceballos C. SPECT scan in somatisation disorder patients: an exploratory study of eleven cases. Aust N Z J Psychiatry 2001;35:359-363.
8. Stoeter P, Bauermann T, Nickel R et al. Cerebral activation in patients with somatoform pain disorder exposed to pain and stress: an fMRI study. Neuroimage 2007;36:418-430.
9. Mullins PG, Rowland LM, Jung RE, Sibbitt WL Jr. A novel technique to study the brain's response to pain: proton magnetic resonance spectroscopy. Neuroimage 2005;26:642-646.
10. Rowland LM, Bustillo JR, Mullins PG et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005;162:394-396.
11. Harris RE, Sundgren PC, Craig AD et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009;60:3146-3152.
12. Valdés M, Collado A, Bargalló N et al. Increased glutamate/glutamine compounds in the brains of patients with fibromyalgia: a magnetic resonance spectroscopy study. Arthritis Rheum 2010;62:1829-1836.
13. Fayed N, Garcia-Campayo J, Magallón R et al. Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther 2010;12:R134.
14. Fayed N, Olmos S, Morales H, Modrego PJ. Physical basis of magnetic resonance spectroscopy and its application to central nervous system diseases. Am J Appl Sci 2006;3:1836-1845.
15. García Campayo J, Rodero B, Alda M, Sobradiel N, Montero J, Moreno S. Validación de la versión española de la Escala de Catastrofización ante el Dolor en la fibromialgia. Med Clin (Barc) 2008;131:487-492.
16. Tejero A, Guimerá EM, Farré JM, Peri JM. Uso clínico del HAD (Hospital Anxiety and Depression Scale) en población psiquiátrica: un estudio de su sensibilidad, fiabilidad y validez. Rev Dep Psiquiatr Fac Med Barc 1986;13:233-238.
17. Lobo A, Saz P, Marcos G et al. Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Med Clin (Barc) 1999;112:767-774.
18. Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: a description and its applications. European Quality of Life scale. Med Clin (Barc) 1999;112(Suppl 1):79-85.
19. Ware JE. SF-36 physical and mental health summary scales: a user's manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
20. Craig AD, Chen K, Bandy D, Reiman EM. Thermosensory activation of insular cortex. Nat Neurosci 2000;3:184-190.
21. Burgmer M, Pogatzki-Zahn E, Gaubitz M et al. Fibromyalgia unique temporal brain activation during experimental pain: a controlled fMRI Study. J Neural Transm 2010;117:123-131.
22. Fayed N, Dávila J, Oliveros A, Castillo J, Medrano JJ. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol 2008;15:1089-1098.
23. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function and relevance to disease. Ann NY Acad Sci 2008;1124:1-38.
24. Maheshwari SR, Fatterpekar GM, Castillo M, Mukherji SK. Proton MR spectroscopy of the brain. Semin Ultrasound CT MR 2000;21:434-451.
25. Provencher SW. Estimation of metabolite concentrations from localised in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
26. Danielsen ER, Ross B. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York, NY: Marcel Dekker, 1999:5-22.
27. Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 2002;6(Suppl A):51-60.
28. Kantarci K, Knopman DS, Dickson DW et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology 2008;248:210-220.
29. Pihlajamäki M, Sperling RA. Functional MRI assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals. Behav Neurol 2009;21:77-91.
30. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004;101:4637-4642.
31. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 2001;15:85-92.
32. Bleich S, Römer K, Wiltfang J, Kornhuber J. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003;18(Suppl 1):S33-S40.
33. Grachev ID, Thomas PS, Ramachandran TS. Decreased levels of N-acetylaspartate in dorsolateral prefrontal cortex in a case of intractable severe sympathetically mediated chronic pain (complex regional pain syndrome, type I). Brain Cogn 2002;49:102-113.
34. Pattany PM, Yezierski RP, Widerström-Noga EG et al. Proton magnetic resonance spectroscopy of the thalamus in patients with chronic neuropathic pain after spinal cord injury. AJNR Am J Neuroradiol 2002;23:901-905.
35. Wood PB, Ledbetter CR, Glabus MF, Broadwell LK, Patterson JC. Hippocampal metabolite abnormalities in fibromyalgia: correlation with clinical features. J Pain 2009;10:47-52.
36. Emad Y, Ragab Y, Zeinhom F, El-Khouly G, Abou-Zeid A, Rasker JJ. Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol 2008;35:1371-1377.
37. Ogura A, Miyamoto M, Kudo Y. Neuronal death in vitro: parallelism between survivability of hippocampal neurones and sustained elevation of cytosolic Ca2+ after exposure to glutamate receptor agonist. Exp Brain Res 1988;73:447-458.
38. Mattson MP, Murrain M, Guthrie PB, Kater SB. Fibroblast growth factor and glutamate: opposing roles in the generation and degeneration of hippocampal neuroarchitecture. J Neurosci 1989;9:3728-3740.
39. Mckenna JE, Melzack R. Blocking NMDA receptors in the hippocampal dentate gyrus with AP5 produces analgesia in the formalin pain test. Exp Neurol 2001;172:92-99.
40. Stern DB. Handedness and the lateral distribution of conversion reactions. J Nerv Ment Dis 1977;164:122-128.
41. Galin D, Diamond R, Braff D. Lateralization of conversion symptoms: more frequent on the left. Am J Psychiatry 1977;134:578-580.
42. Min SK, Lee BO. Laterality in somatization. Psychosom Med 1977;59:236-240.
43. Roelofs K, Näring GW, Moene FC et al. The question of symptom lateralization in conversion disorder. J Psychosom Res 2000;49:21-25.